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ABSTRACT 21 
The in vitro antithrombotic properties of polar lipid microconstituents of three Irish beers 22 
(ale, larger, and stout) have been assessed against platelet-activating factor-induced platelet 23 
aggregation. Total lipid (TL) extracts were obtained using the Bligh and Dyer method and 24 
each beer was separated into the organic phase and hydromethanolic phase. The total polar 25 
lipid (TPL) and total neutral lipid (TNL) fractions of the organic phase and hydromethanolic 26 
phase of each beer were obtained using a counter-current distribution. The TL, TNL, and 27 
TPL extracts of each phase of each beer were measured for their capacity to inhibit platelet-28 
activating factor-induced platelet aggregation. The low IC50 values obtained suggest that all 29 
three beers contain potent polar lipids that can inhibit platelet-activating factor-induced 30 
platelet aggregation. The fatty acid composition of the organic phase TPL extracts were 31 
measured using gas chromatography-mass spectrometry. The organic phase total polar lipid 32 
extracts were further fractionated using thin-layer chromatography (TLC) and the 33 
antithrombotic bioactivities of these TLC bands were measured. This data suggested that the 34 
TLC bands corresponding to phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, 35 
and cardiolipin were the most active phospholipids in the total polar lipids of the organic 36 
phase. These promising results indicate that beer consumption may provide antithrombotic 37 
effects.  38 
 39 
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 44 
1. Introduction 45 
Cardiovascular diseases (CVD) are the leading cause of death globally. Diet and 46 
lifestyle are key modifiable risk factors for the prevention of CVD. The relationship between 47 
alcohol consumption and human health is complex and the harmful effects of alcohol are 48 
well-established in contrast to the beneficial effects. Excessive alcohol consumption has been 49 
linked to several chronic diseases including cancers (Schwarzinger et al., 2017).  50 
 Moderate alcohol consumption has, however, been associated with several health 51 
benefits. Alcohol consumption in moderation (1-2 drinks/day) is associated with positive 52 
effects against a number of cardiovascular risk factors including an increase in high-density 53 
lipoprotein (HDL) cholesterol, reduced fibrinogen levels, and reduced platelet aggregation, 54 
which have all been attributed to the ethanol and polyphenol content of alcoholic beverages 55 
(Arranz et al., 2012, de Gaetano et al., 2016). Large epidemiological studies have shown that 56 
moderate alcohol consumption significantly reduces cardiovascular risk factors, morbidity, 57 
and mortality through a dose-effect relationship that is characterised by a J-shaped curve (de 58 
Gaetano et al., 2016). In addition, beer has been associated with a lower risk of ischemic 59 
stroke when 1 to 6 servings of beer/wk was consumed (Mukamal et al., 2005). Furthermore, a 60 
recent 12-wk prospective study with overweight individuals has shown that moderate 61 
consumption of traditional and non-alcoholic beer did not affect lipid levels, but significantly 62 
increased the antioxidant capacity of high-density lipoprotein (HDL). In addition, apoB-63 
depleted serum (after the 4-wk intervention period) showed a higher potential to promote 64 
cholesterol efflux from macrophages, which may prevent lipid deposition in the vessel wall 65 
(Padro et al., 2018). 66 
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Systemic inflammation and thrombosis are the dominant mechanism for the pathology 67 
of CVD (Tsoupras et al., 2018b). Platelet-activating factor (PAF) is a strong phospholipid 68 
mediator implicated in the onset and progression of atherosclerosis (Lordan et al., 2017, 69 
Lordan and Zabetakis 2017). PAF and PAF-like molecules function through their binding to 70 
the PAF-receptor (PAF-R), which can lead to the activation of multiple intracellular 71 
pathways and subsequent thrombosis (Lordan et al., 2017, Tsoupras et al., 2018b). The 72 
relationship between PAF and the PAF-R is the target of several therapeutic approaches, due 73 
to the high specificity of PAF for its receptor. Inhibition of this binding leads to an 74 
amelioration of the PAF inflammatory pathways and thrombotic response (Lordan et al., 75 
2018b). Previous studies have shown that dietary polar lipids in marine (Lordan et al., 2017, 76 
Tsoupras et al., 2018a) and dairy products (Megalemou et al., 2017) inhibit PAF-induced 77 
platelet aggregation. Similarly, polar lipids of wine, yeasts, grapes and their skins can reduce 78 
PAF-induced platelet aggregation and modulate PAF metabolism in both postprandial and in 79 
vitro studies (Xanthopoulou et al., 2014, Xanthopoulou et al., 2016, Argyrou et al., 2017). 80 
The effects of wine consumption have been attributed to the presence of polar lipid 81 
microconstituents and phenolic compounds (Lordan et al., 2018a).   82 
However, less is known about the effects of beer against PAF and CVD. The purpose 83 
of this study was to measure the antithrombotic properties of polar lipid microconstituents in 84 
three commercial beers produced in Ireland against PAF-induced platelet aggregation.   85 
 86 
2. Materials and methods 87 
2.1. Chemicals and reagents 88 
 All solvents and glassware used were purchased from Fisher Scientific Ireland Ltd. 89 
(Dublin, Ireland). All chemical reagents used for platelet aggregometry and lipid standards 90 
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for GC-MS and TLC, and TLC plates were purchased from Sigma-Aldrich (Wicklow, 91 
Ireland). All platelet aggregometry consumables were purchased from Labmedics LLP 92 
(Abingdon on Thames, UK). All GC-MS consumables were purchased from Apex Scientific 93 
Ltd. (Kildare, Ireland).  94 
2.2. Samples used 95 
 Three popular commercial draught beers were obtained at the University of Limerick 96 
campus student bar. A stout (Guinness), a lager (Hop House 13), and an ale (Smithwick’s, 97 
Diageo, Dublin, Ireland) were selected for this study. Each sample was freshly obtained three 98 
times from a different beer keg into a polypropylene tube and was transported 200 m to the 99 
laboratory for immediate extraction. 100 
2.3. Lipid extraction in the organic phase (OP) and hydromethanolic phase (HMP) 101 
 The total lipids (TL) of each beer were extracted in triplicate using the method of 102 
Bligh and Dyer (1959), which is an extraction method using chloroform, methanol, and water 103 
that was added to the sample to extract lipid in a ratio of 1:2:0.8 initially. However, as beer is 104 
almost completely water, no water was added. The samples were then filtered under vacuum 105 
using Whatman 1 filter paper (Fisher Scientific Ltd., Dublin, Ireland) and the filtrate was then 106 
transferred to a separating funnel, where the solvents were adjusted to 1:1:0.9 chloroform, 107 
methanol, and water respectively, to create a biphasic system. The lower organic phase (OP) 108 
had most of the lipid content dissolved in chloroform and the upper hydromethanolic phases 109 
(HMP) mainly contained methanol, water, and other components, such as glycolipids and 110 
polyphenolic compounds. Each phase was evaporated to obtain the lipids and compounds 111 
present in the beers using rotary evaporation at 40°C under vacuum (Buchi R-100 Rotavapor, 112 
Mason Technology Ltd., Dublin, Ireland) and a tenth of each TL was stored under nitrogen at 113 
-20°C for a maximum of 6 months. The remaining constituents of each phase were subjected 114 
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to counter-current distribution using 87% ethanol and petroleum ether (40-60°C b.p.) to 115 
create a biphasic system as previously described (Galanos and Kapoulas 1962). In brief, in a 116 
separatory funnel the TL of the OP and HMP were dissolved in 9 ml of petroleum ether and 3 117 
ml of 87% ethanol or in a sufficient volume of these solvents in a ratio of 3:1 respectively. 118 
This separated the total polar lipids (TPL) in the lower ethanol layer from the  total neutral 119 
lipid (TNL) extracts in the upper petroleum ether layer. The ethanol layer was transferred to 120 
another separatory funnel that contained 9 ml of petroleum ether to create a biphasic system. 121 
The lower ethanol layer that contained the TPL was then transferred to a round-bottomed 122 
flask. The remaining petroleum ether in both separatory funnels was transferred to another 123 
round-bottom flask to obtain the TNL. Both the TNL and TPL were obtained using rotary 124 
evaporation of each phase at 40°C under vacuum. Extracted lipids were stored dry in glass 125 
vials under nitrogen at -20°C until required or for a maximum of 6 months.    126 
2.4. Preparative thin-layer chromatography (TLC) 127 
 The fractionation of the TPL from the OP and the HMP of each beer sample was 128 
carried out in triplicate as previously described (Nasopoulou et al., 2007, Tsoupras et al., 129 
2018a). In brief, 6 mg of dried TPL of each phase was diluted in 100 µl of chloroform and 130 
methanol (1:1) and applied to the concentration zones of 1 mm silica G60 TLC plates (Merck 131 
Millipore Ltd., Carrigtohill, Co. Cork, Ireland). The mobile phase was chloroform, methanol, 132 
and water in a ratio of 65:35:6 (v/v/v). A phospholipid standard from eggs was used as a 133 
control and lipids were stained using iodine vapours for comparative identification by 134 
comparing retention factors versus the standards. Following the evaporation of the iodine 135 
vapours, the bands were scraped, and lipids were extracted from the silica gel using the 136 
method of Bligh and Dyer (1959). The chloroform phase was evaporated to dryness under 137 
nitrogen and lipids were weighed, re-dissolved in 1 ml of chloroform:methanol 1:1 (v/v), and 138 
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stored at −20°C in nitrogen until further analysis for a maximum of 2 wk as previously 139 
described (Tsoupras et al., 2018a).  140 
2.5. Platelet aggregation assay 141 
 Healthy human volunteers (n=12) gave informed consent and all experiments were 142 
done in accordance with the Declaration of Helsinki after ethical approval was granted by the 143 
University of Limerick Ethics Committee. Blood collection and analysis was done as 144 
previously described (Tsoupras et al., 2018a). In brief, fasting blood samples were donated by 145 
volunteers who were not receiving anti-platelet therapy. In total, 50 ml of blood was obtained 146 
using venepuncture of the median cubital vein using a 20G needle. Blood was drawn into 147 
evacuated sodium citrate S-monovettes using the aspiration method (0.106 mol/l in a 1:10 148 
ratio of citrate to blood; Sarstedt Ltd., Wexford, Ireland), followed by immediate 149 
centrifugation at 180 x g for 18 min at 24°C (Eppendorf 5702 R, Eppendorf Ltd., Stevenage, 150 
UK) to obtain the platelet-rich plasma (PRP). A second centrifugation at 1,500 x g for 20 min 151 
at 24°C was carried out to obtain the platelet-poor plasma (PPP). The PRP was standardised 152 
to 500,000 platelets µl-1, if required, by adding an appropriate volume of PPP to the PRP until 153 
the absorbance was 0.8 at 530 nm using a Shimadzu UV-1800 spectrophotometer (Kyoto, 154 
Japan), prior to analysis on a Chronolog-490 two channel platelet aggregometer, coupled to 155 
the accompanying AGGRO/LINK software package (Chronolog, Havertown, PA, USA). 156 
Lipid samples and PAF were dissolved in a solution of BSA-saline (2.5 mg BSA/ml saline). 157 
Prior to testing, 250 µl of PRP was added to an aggregometer cuvette at 37°C with stirring at 158 
1000 rpm. The PRP was calibrated using the PPP as a blank. PAF was added to the cuvettes 159 
to induce maximum reversible aggregation (2.6 x 10-8 M, final concentration in the cuvette), 160 
and 50% PAF-induced aggregation was calculated. Subsequently, the IC50 was calculated as 161 
previously described (Tsoupras et al., 2018a). Briefly, the PAF-induced aggregation was 162 
calculated first at 0% inhibition of baseline in a cuvette. In a different cuvette PRP was 163 
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preincubated with the test samples at a variety of concentrations for 1 min and the same 164 
concentration of PAF was added and the reduction of platelet aggregation was calculated. 165 
Thus, a linear curve at the 20–80% range of the percentage of inhibition against PAF-induced 166 
aggregation of PRP to the concentrations of each sample was obtained. From this curve, the 167 
concentration of the sample that led to 50% of PAF-induced aggregation of PRP was 168 
calculated as the 50% inhibitory concentration, also known as the IC50 value, for each lipid 169 
extract. Each TPL, TNL, and TL experiment was carried out in sextuplicate and each TLC 170 
band was measured in triplicate following appropriate control tests.  171 
2.6. Gas chromatography-mass spectrometry 172 
 Fatty acid methyl esters (FAME) were prepared and analysed in triplicate using 35 173 
mg of the OP beer TPL samples as previously described (Tsoupras et al., 2018a). In brief, 174 
FAME were derivatised using a 0.5 M KOH in 90% CH3OH and extracted with n-hexane. 175 
Analysis was carried out using the internal standard method as extensively described 176 
(Tsoupras et al., 2018a). In brief, a 5-point calibration curve was prepared using 5 solutions 177 
of heptadecanoic acid (17:0—50, 100, 200, 400, and 800 ppm) and heneicosanoic acid 178 
(21:0—5 500 ppm injections) methyl ester standards. Five 1 µl injections of each solution 179 
were analysed using a Varian 410-Gas Chromatographer coupled to a Varian 210-MS 180 
detector equipped with a split/splitless injector (Agilent Technologies, Santa Clara, CA, 181 
USA). The ratio of the mean of heptadecanoic acid to that of the internal standard 182 
heneicosanoic acid was used as the y-axis variable, whereas the concentration (ppm) of 17:0 183 
was used as the x-axis variable of the calibration curve. The equation that described the curve 184 
was: y = 0.0041x + 0.12 with an R2 = 0.9969, where the ratio of the area of the analyte peak 185 
to that of the internal standard represents the y value for the above equation and the x value 186 
represents the analyte concentration of a selected fatty acid in the lipid sample. FAME and 187 
standards were separated using an Agilent J&W DB-23 fused silica capillary column (60 m, 188 
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0.25 mm, i.d., 0.25 µm; Agilent Technologies). The injector temperature was set at 230°C 189 
with a split ratio of 1:5. The carrier gas was high purity helium with a liner flow rate of 1 190 
ml/min. The oven temperature was initially programmed to 100°C for 5 min, raised to 240°C 191 
at 3°C/min, and finally held isothermally at 240°C for 10 min. Identification of FAME was 192 
done using a pre-derivatised 37-component FAME standards mix by comparison of the 193 
retention times and mass spectra of relative peaks with the aid of the Varian Star 194 
Chromatography Workstation Version 6 software (Agilent Technologies) and a NIST mass 195 
spectrum library CD (Gaithersburg, MD, USA).  196 
2.7. Statistical analysis 197 
 All biological analyses were completed in sextuplicate and all extractions and GC-MS 198 
analyses were completed in triplicate. The results were expressed as a mean value ± standard 199 
deviation (SD). One-way analysis of variance (ANOVA) and Fisher’s LSD multiple 200 
comparison test (p ≤ 0.05) was used to find the significant statistical differences between 201 
analyses using the Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA). 202 
 203 
3.  Results and discussion 204 
3.1. Lipid extraction and fractionation of ale, lager, and stout 205 
 The TL, TNL, and TPL content of the OP and the HMP phases are shown in Table 1. 206 
The stout had a significantly higher amount of TL in the OP in comparison to the ale or lager. 207 
However, the TNL fraction of the OP and the HMP of all three beers were low. This agrees 208 
with previously observed low levels of lipids in beer (Anness 1984, Cozzolino and Degner 209 
2016). Although considerable amounts of lipids are present in the raw materials used in beer 210 
production (Hough et al., 1982), such as malted barley, hops and yeasts, only trace amounts 211 
remain in the final product. This may be due to a 30% loss of lipid during the germination of 212 
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barley, as fatty acids are released by hydrolysis of triglycerides, which are then metabolised 213 
(Anness 1984). In addition, a significant proportion of the lipid content is lost to the spent 214 
grains generated during the brewing process (Cozzolino and Degner 2016). Lipids are also 215 
actively reduced in beer production due to their negative effects on beer flavour and foam 216 
stability. In the HMP there was no statistically significant difference between the mass of 217 
samples. Interestingly, the TL of the OP is significantly lower than that of the HMP. This 218 
may in part be due to the presence of glycolipids, galactolipids, and phenolic-lipids that are 219 
present in beers (Marion et al., 2003), which would have more affinity to the HMP due their 220 
amphipathic properties.   221 
*Insert Table 1 Here*  222 
3.2.Thin-layer chromatography separation 223 
 The TPL fraction of the OP and the HMP were further separated into their constituent 224 
phospholipid subclasses using TLC. The predominant TLC bands of the TPL fraction of the 225 
OP and the HMP showed similar Rf values to phosphatidylcholine (PC), 226 
phosphatidylethanolamine (PE), cardiolipin (CL), and sphingomyelin (SM) (Figure 1). 227 
Notably, the TLC bands of the TPL fraction of HMP of the lager showed much higher iodine 228 
staining than the corresponding ones of the other two beers, this may be due to the presence 229 
of more unsaturated compounds in the lager HMP, such as phenolic compounds, which are 230 
abundant in beer (Marion et al., 2003).  231 
3.3.Gas chromatography-mass spectrometry analysis 232 
 The fatty acid profiles of the TPL of the OP of all samples were analysed using GC-233 
MS (Table 2). All three beers showed a distinctive lipid profile probably due to the different 234 
cultivars and growing conditions of the barley and hops used in the production process, and 235 
the fermentation process itself, which is influenced by the metabolism of the yeasts used 236 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Running title: In vitro antithrombotic properties of three types of beer 
 
(Cozzolino and Degner 2016). Yeasts used in the fermentation process have the capacity to 237 
alter several lipid species, including phospholipids and polyunsaturated fatty acids (PUFA) 238 
(Moonjai et al., 2003). Most of the fatty acids that yeast metabolise are due to extracellular 239 
hydrolysis of lipids, microsomal alkane oxidation, and exogenously in the brewing materials, 240 
wort, and filtered beer. Yeasts also generate lipases that degrade triglycerides, subsequently 241 
the free fatty acids are utilised in the synthesis of long-chain fatty acids (Moonjai et al., 2002, 242 
Moonjai et al., 2003). During beer maturation, the levels of short chain volatile acids are 243 
reduced because yeasts use them to biosynthesise glycerides and phospholipids (Briggs et al., 244 
2004).  245 
 Stout beer TPL had lower levels of MUFA and PUFA species and higher levels of 246 
SFA (10:0, 12:0, 13:0, 16:0, 18:0, 22:0) compared to the other beers. The roasting of the malt 247 
for stout requires high heat in excess of 200°C to induce the Maillard reaction (Bamforth 248 
2014). Unsaturated fats are highly susceptible to oxidation and degradation and therefore the 249 
malting process in stout production may reduce the levels of PUFA and MUFA (22:1, 250 
22:2ω3, and 22:4ω3 were not detected) and increase the levels of SFA. Both the ale and lager 251 
share similar lipid profiles, however the TPL of ale had greater levels of MUFA and PUFA in 252 
comparison to the lager. In particular, 22:1ω3 and 22:4ω3 were in greater abundance in the 253 
ale than the lager. However, 22:2ω3 was not detected in the ale, but was present in the lager.  254 
*Insert Table 2 here* 255 
3.4. Platelet aggregation assay analysis 256 
 The TL, TNL, and TPL of the OP and HMP of each beer sample were measured for 257 
their ability to inhibit PAF-induced platelet aggregation in PRP. The results are shown in 258 
Table 3 and are expressed as an IC50 value, which is the mass of lipid in micrograms (µg) 259 
required to induce the half maximal inhibitory concentration of PAF-induced platelet 260 
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aggregation. All lipid samples tested showed strong activity against PAF-induced platelet 261 
aggregation. Notably, the TPL and TL showed greater bioactivity than the TNL of all 262 
samples, which is in accordance with previous studies in dairy (Megalemou et al., 2017) and 263 
wine (Fragopoulou et al., 2001) with one notable exception: the TNL of the HMP of stout 264 
showed an extremely low IC50. Interestingly, the OP TL showed bioactivity comparable to 265 
the TPL of the lager and ale, indicating that the combination of the TPL and TNL fractions 266 
may show synergistic effects against PAF-induced platelet aggregation. Furthermore, it is 267 
possible that the presence of phenolic compounds  in the TPL of both the OP and HMP of 268 
each beer may have a role in the bioactivity of these lipid fractions, since such polar lipids are 269 
present in high amounts relative to the neutral lipids (Marion et al., 2003), while similar anti-270 
PAF effects were observed with phenolic compounds found in wine and yucca (Balestrieri et 271 
al., 2006, Tsoupras et al., 2007). This would account for the strong antithrombotic effects 272 
observed in TL and TPL samples of the HMP, since such polar lipids seem to have an affinity 273 
for hydrophilic phases. However, further research is required to confirm these observations.  274 
 Although the bioactivity of the TPL of OP of stout showed a considerable anti-PAF 275 
effect, it was less potent that the other TPL fractions of ale and lager. This may be due to 276 
variances in the raw materials used or the brewing process or due to the roasting of the malt 277 
for stout production (Bamforth 2014), during which oxidation and degradation of unsaturated 278 
fats can occur and may account for the loss of bioactivity. Finally, the separation of the OP 279 
TPL fractions using TLC and subsequent analysis against PAF-induced platelet aggregometry 280 
indicated that PC, PE, SM, and CL phospholipid species showed the most potent anti-PAF 281 
effects, while their coexistence in the TPL fraction of the OP seems to induce a synergistic 282 
effect that may be responsible for the potent anti-PAF activities observed in the TPL 283 
fractions, which is in agreement with previous data published on salmon (Tsoupras et al., 284 
2018a), meat (Poutzalis et al., 2018), and dairy (Megalemou et al., 2017) lipids. Equally, the 285 
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presence of hydrophilic compounds such as glycolipids and phenolic compounds may affect 286 
these bioactivities as has previously been reported in wine (Fragopoulou et al., 2001, 287 
Fragopoulou et al., 2002), particularly in relation to the TL and TNL extracts.   288 
*Insert Table 3 here* 289 
*Insert Figure 1 here* 290 
 291 
4. Conclusions 292 
 It was shown that polar lipids present in the OP and HMP of ale, lager, and stout 293 
showed potent inhibition of PAF-induced human platelet aggregation in vitro. These potent 294 
bioactivities of the TPL fractions of both the OP and HMP may be due to the presence and 295 
synergistic effects of PC, PE, SM, and CL derivatives, and the presence of other hydrophilic 296 
compounds such as glycolipids and phenolic compounds. Furthermore, GC-MS analysis 297 
indicated that the stout OP TPL extracts had a lower level of MUFA and PUFA and a 298 
statistically significantly higher level of SFA in comparison to the ale and lager, which may 299 
account for the slightly higher IC50 values. However, further research is suggested to 300 
determine the structures of the bioactive compounds present in beer and to determine if they 301 
show similar ex vivo activity to wine. Notably, polar lipids may enhance foaming in beer due 302 
to their emulsification properties, therefore an increase of polar lipids in beer would benefit 303 
their techno-functional properties and potentially provide health benefits against 304 
inflammation and thrombosis.  305 
 306 
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 444 
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 446 
 447 
 448 
 449 
 450 
 451 
Figure Legend: 452 
Fig. 1. The mean IC50 (µg) values for each of the TPL bands isolated using TLC of the OP 453 
with error bars of standard deviation (mean ± SD, n = 3). In the image incorporated, a 454 
representative TLC separation of the phospholipid classes present in the OP and HMP of the 455 
ale, lager, and stout TPL. Lane 1 contains the hen egg yolk phospholipid standard. Lanes 2, 4, 456 
and 6 contain the TPL of the OP ale, stout, and lager, respectively. Lanes 3, 5, and 7 contain 457 
the TPL of the HMP of the ale, stout, and lager, respectively. Due to the lack of 458 
phospholipids in the HMP, these bands were not further analysed using platelet 459 
aggregometry. a,b,c denotes the statistically significant differences (p  ≤  0.05) between 460 
phospholipids of the same TLC band of each beer. Abbreviations: CL = cardiolipin; HMP = 461 
hydro-methanolic phase; L-PC = lyso-phosphatidylcholine; L-PE = lyso-462 
phosphatidylethanolamine; OP = organic phase; PC = phosphatidylcholine; PE = 463 
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phosphatidylethanolamine; SM = sphingomyelin; TLC = thin-layer chromatography; TPL = 464 
total polar lipid  465 
 466 
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 488 
Table 1  489 
Content of total lipids (TL), total polar lipids (TPL) and the total neutral lipids (TNL), 490 
expressed in g/100 g of beer and the TNL and TPL are expressed as a percentage of the total 491 
lipid (mean ± SD, n = 3) in the OP and HMP of the stout, ale, and lager.  492 
OP TL (g/100g beer) TPL (g/100g beer) TPL (% TL) TNL (g/100g beer) TNL (% TL) 
Stout  0.03 ± 0.01a 0.03 ± 0.01a 98 ± 16a 0.001 ± 0.00a 3.7 ± 0.2a 
Ale 0.02 ± 0.02a 0.01 ± 0.002b 43 ± 9b 0.001 ± 0.00a 4.5 ± 0.5b 
Lager 0.02 ± 0.01a 0.01 ± 0.004b 60 ± 21b 0.003 ± 0.00a 15 ± 1c 
HMP TL (g/100g beer) TPL (g/100g beer) TPL (% TL) TNL (g/100g beer) TNL (% TL) 
Stout 0.06 ± 0.02a 0.04 ± 0.02a 66 ± 27a 0.003 ± 0.00a 4.4 ± 0.4a 
Ale 0.05 ± 0.01a 0.05 ± 0.01a 94 ± 25b 0.002 ± 0.00a 4.5 ± 0.4a 
Lager 0.08 ± 0.03a 0.05 ± 0.03a 64 ± 37a 0.002 ± 0.00a 2.9 ± 0.2b 
a,b,c
 Different superscripts indicate significant differences among different lipid extracts within 493 
the same lipid class (p ≤ 0.05) of either OP (organic phase) or HMP (hydromethanolic phase). 494 
  495 
 496 
 497 
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 510 
Table 2 511 
Fatty acid profile of total polar lipids (TPL) of each sample expressed in percentage (%) of 512 
total fatty acids of each beer sample (mean ± SD, n = 3). Total SFA, MUFA, and PUFA are 513 
shown as a percentage of total lipid. 514 
 
Fatty Acid 
 
 
Stout 
 
Ale 
 
Lager 
 
10:0 Decanoic acid 2.3 ± 1.1a 0.02 ± 0.02b 0.16 ± 0.00b 
12:0 Dodecanoic acid 2.3 ± 0.9a 0.13 ± 0.80b 0.48 ± 0.01b 
12:1 Dodecenoic acid 5.1 ± 0.5a ND 1.1 ± 0.0b 
13:0 Tridecanoic acid 0.17 ± 0.02a 0.07 ± 0.06b ND 
13:1 Tridecenoic acid 1.8 ± 0.1a 0.05 ± 0.06b ND 
14:0 Tetradecanoic acid 1.1 ± 0.1b 2.9 ± 2.8ab 0.57 ± 0.01a 
14:1  Tetradecenoic acid 7.5 ± 0.4a 0.05 ± 0.03c 4.4 ± 0.1b 
15:0 Pentadecanoic acid 0.95 ± 0.10b 0.04 ± 0.09c 1.55 ± 0.03a 
15:1 Pentadecenoic acid 2.1 ± 0.1a 0.25 ± 0.10b 0.79 ± 0.02c 
16:0 Hexadecanoic acid 22 ± 1a 8.7 ± 7.5b 14 ± 0.3b 
16:1 Hexadecenoic acid 1.8 ± 0.2a 1.2 ± 1.1ab 1.52 ± 0.03b 
17:0 Heptadecanoic acid ND 0.07 ± 0.05b 0.54 ± 0.01a 
17:1  Heptadecenoic acid 1.2 ± 0.1a 0.45 ± 0.21b 0.47 ± 0.01b 
18:0 Octadecanoic acid 9.1 ± 0.5a 3.9 ± 1.0b 6.3 ± 0.1c 
18:1ω9 Octadecenoic acid 16 ± 1a 6.8 ± 5.7b 10 ± 0.2b 
18:2ω6 Octadecadienoic acid 7.4 ± 0.8a 5.7 ± 2.2a 1.46 ± 0.03b 
18:3ω3 Octadecatrienoic acid 3.3 ± 0.1a 1.2 ± 1.1b 1.22 ± 0.02b 
20:4ω6 Eicosatetraenoic acid 13 ± 3a 8.4 ± 4.5a 2.4 ± 0.1b 
22:0 Docosanoic acid 2.6 ± 1.6 ND ND 
22:1  Docosenoic acid ND 33 ± 16a 24 ± 0.5a 
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a,b,c
 Mean values (n = 3), ± standard deviation with different letters in the same row indicating 515 
statistically significant differences between the lipid compositions (p ≤ 0.05). Abbreviation: 516 
MUFA = monounsaturated fatty acids; ND: non-detectable; PUFA = polyunsaturated fatty 517 
acids; SFA = saturated fatty acids 518 
 519 
 520 
 521 
 522 
 523 
Table 3  524 
The in vitro biological activities of the total lipids (TL), total neutral lipids (TNL), and total 525 
polar lipids (TPL) of the organic phase (OP) and hydromethanolic phase (HMP) of ale, lager, 526 
and stout against PAF-induced human platelet aggregation, expressed as an IC50 in 527 
micrograms (µg) of sample. The hPRP concentration was approximately 500,000 platelets µl-528 
1
. The final concentration of PAF in the cuvette was 2.6 x 10-8 M. All experimental analyses 529 
were carried out in sextuplicate (n=6).  530 
a,b,c
 Different superscripts indicate significant differences among different lipid extracts 531 
within the same lipid class (p ≤ 0.05).  532 
 533 
 534 
22:2ω3 Docosadienoic acid ND ND 8.1 ± 0.2 
22:4ω3 Docosatetraenoic acid ND 26 ± 13a 16 ± 0.3a 
SFA  41 ± 5a 16 ± 12b 24 ± 0.5b 
MUFA  35 ± 3a 42 ± 24ab  41 ± 1b 
 
PUFA 
 
24 ± 3a 41 ± 21ab 30 ± 1b 
Sample Organic Phase  Hydromethanolic Phase  
 TL TNL TPL TL TNL TPL 
Stout 14 ± 3a 59 ± 10b 38 ± 10b 21 ± 9a 11 ± 3a  40 ± 10b 
Ale 13 ± 2a 57 ± 10b 11 ± 3a 15 ± 3a 90 ± 20b 6 ± 1a 
Lager 11 ± 2a 340 ± 40a 16 ± 7a 16 ± 5a 150 ± 20c 5 ± 1a 
